Year All20232022 11/09/2023 Third Harmonic Bio Announces Third Quarter 2023 Financial Results 10/31/2023 Third Harmonic Bio Announces Leadership Changes 08/31/2023 Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference 08/10/2023 Third Harmonic Bio Announces Second Quarter 2023 Financial Results 07/25/2023 Third Harmonic Bio Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335 05/11/2023 Third Harmonic Bio Announces First Quarter 2023 Financial Results 03/29/2023 Third Harmonic Bio Announces Fourth Quarter and Year-End 2022 Financial Results 12/15/2022 Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria 11/21/2022 Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference 11/09/2022 Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update
12/15/2022 Third Harmonic Bio Announces Discontinuation of Phase 1b Study of THB001 in Chronic Inducible Urticaria
11/21/2022 Third Harmonic Bio to Participate in Fireside Chat at the Evercore ISI 5th Annual HealthCONx Conference
11/09/2022 Third Harmonic Bio Announces Third Quarter 2022 Financial Results and Provides Corporate Update
